134
Participants
Start Date
July 23, 2025
Primary Completion Date
August 31, 2029
Study Completion Date
August 31, 2030
Tislelizumab
During ChemoImmunotherapy: Patients in the investigational arm will receive 8 cycles of tislelizumab 150 mg IV on Day 1, followed by mFOLFOX6 (Q2W).
Total neoadjuvant therapy (TNT)
Patients will be treated with 6 weeks of capecitabine-based CRT followed 4 weeks later by 16 weeks of chemotherapy with mFOLFOX6, Q2W.
NOT_YET_RECRUITING
Johannes Gutenberg-University Clinic, Mainz, Germany 1.Dept. Medicine, Prof. Peter R. Galle, Mainz
RECRUITING
Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva
Johannes Gutenberg University Mainz
OTHER
brenner baruch
OTHER